Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M

SERA PROGNOSTICS, INC.

Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
PRIME study: 25% reduction in neonatal morbidity/mortality index and 18% reduction in length of stay in modified ITT.
Full year 2024 revenue $77,000; net loss $32.9M vs $36.2M in 2023.
Raised $57.5M in Feb 2025 public offering; cash runway extended through 2028.
R&D expenses $3.1M in Q4, down 19% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.